Jan 29 (Reuters) - Sorrento Therapeutics Inc:
* CHINA ONCOLOGY FOCUS LIMITED RECEIVES APPROVAL BY CHINESE AUTHORITIES TO BEGIN CLINICAL TRIALS IN THREE SEPARATE CANCER INDICATIONS USING SORRENTO’S ANTI-PD-L1 MONOCLONAL ANTIBODY
* SORRENTO THERAPEUTICS - ‍CLINICAL DATA FROM STUDIES COULD BE AVAILABLE BY END OF YEAR 2019​ Source text for Eikon: Further company coverage:
 